$TEM

Rogers James William sold $634K of TEM

Rogers James William (Chief Financial Officer) sold 11,529 shares of Tempus AI, Inc. (TEM) at $55.00 ($0.63M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rogers James William
Published Jun 30, 2026, 12:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The disclosed event is an open-market sale by the CFO for ~$634k, executed under a pre-arranged 10b5-1 plan; this is generally treated as routine unless paired with other negative fundamentals.

02

Market read

Traders may monitor for insider selling trends, but this specific disclosure is unlikely to drive a major repricing on its own.

03

What to watch

The filing does not disclose reasons for the sale beyond the existence of a 10b5-1 plan; without additional context (e.g., other insiders buying, earnings timing), the signal is weak.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed late June 29; sale dated June 25.

Background

The article summarizes an SEC Form 4 insider transaction for Tempus AI, Inc. (TEM) involving the CFO.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI CFO Rogers James William sold 11,529 shares in an open-market transaction for about $634,095 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale (not a buy), but it is explicitly tied to a pre-arranged 10b5-1 plan, reducing the likelihood of new, time-sensitive negative information.

Market effects

Minimal—this is company-specific insider transaction data with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still reflect management’s view of valuation or liquidity needs; traders may still fade rallies if selling cadence continues.

Key entities

  • Tempus AI, Inc.

    Issuer of the Form 4 insider transaction; ticker TEM.

  • Rogers James William

    Chief Financial Officer who sold 11,529 shares.

  • 10b5-1 plan

    Pre-arranged trading plan that reduces the informational content of the sale timing.

Related articles

$TEMMed

Why Is Tempus AI Stock Surging on Friday? - Tempus AI (NASDAQ:TEM)

Tempus AI Inc. (NASDAQ:TEM) shares rose about 11% on Friday, outperforming the Nasdaq and the Healthcare sector, amid an AI-healthcare sector rally. The move followed strong peer results, including Doximity’s fiscal Q1 revenue of $156.6 million, and a strategic collaboration with CellCarta adding Tempus to its CDx lab network. TEM traded near $50.95.

$TEMMed

BTIG cuts Tempus AI stock price target to $70 on model update

BTIG cut its Tempus AI (NASDAQ:TEM) price target to $70 from $80 while keeping a Buy rating after the company’s Q2 2026 earnings call. Tempus AI reported 22% YoY revenue growth, raised 2026 revenue guidance to 25% to 26%, and posted $382.5M revenue with an adjusted EPS loss of $0.04. BTIG cited Tempus’s $1.5B Personalis deal with a $46 stock-price termination trigger.

$TEMMedAI 8/10

Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

$TEMMedAI 8/10

Tempus AI Raises FY2026 Sales Guidance to $1.595B-$1.605B

Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion.

$TEMMedAI 8/10

Tempus AI Q2 Results: Revenue rises 22% YoY, stock slides

Tempus AI (NASDAQ: TEM) reported second-quarter revenue of $382.5 million, rising 22% year-over-year and surpassing Street consensus estimates of $379.7 million. Despite the top-line beat and a narrower-than-expected loss per share of four cents versus an estimated 14 cents loss, shares declined 2.4% in after-hours trading to $43.25.